Floatz logo

68ga-p16-093

Prostate Cancer (Adenocarcinoma)

First Affiliated Hospital of Fujian Medical UniversityradiopharmaceuticalPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
81/ 100

Competitive context

96 Active assets in the Prostate Cancer (Adenocarcinoma) cohort.

Asset / SponsorPhaseRating
Docetaxel
Instituto do Cancer do Estado de São Paulo
Phase 3BBB
Degarelix
Canadian Cancer Trials Group
Phase 3BB
PREDNISONE TABLETS
Mayo Clinic
Phase 3BB
NILUTAMIDE
SWOG Cancer Research Network
Phase 3BB
Cyclophosphamide
Beijing Biotech
Phase 2BB

View all 50 →

Same molecule, other indications

68ga-p16-093 is also rated in:

prostate cancerDormant
CCC
Indicative ·
48 / 100
View asset →
nonpapillary renal cell carcinomaDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →